Accelerated Approval and Possible Withdrawal of Midodrine

被引:33
作者
Dhruva, Sanket S. [1 ]
Redberg, Rita F. [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 19期
关键词
D O I
10.1001/jama.2010.1695
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:2172 / 2173
页数:2
相关论文
共 9 条
[1]
Surrogate endpoints and FDA's accelerated approval process [J].
Fleming, TR .
HEALTH AFFAIRS, 2005, 24 (01) :67-78
[2]
*GEN, 2010, GEN PROV UPD AV ADV
[3]
HARRIS G, 2010, NY TIMES 0903
[4]
NAINGGOLAN L, FDA DOES U TURN MIDO
[5]
POLLACK A, 2010, NY TIMES 0917
[6]
Are surrogate markers adequate to assess cardiovascular disease drugs? [J].
Temple, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (08) :790-795
[7]
U.S. Government Accounting Office, 2009, NEW DRUG APPR FDA NE
[8]
*US FDA, 2010, FDA PROP WITHDR LOW
[9]
*US FDA, 2010, MID UPD SEPT 10